These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 26267985)

  • 1. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?
    Qunibi WY; Abdellatif A; Sankar S; Hamdan Z; Lin FY; Ingle J; Cadena A; Gelfond J; Kasinath B
    Clin Nephrol; 2010 Apr; 73(4):276-85. PubMed ID: 20353735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.
    Al-Aly Z; Qazi RA; González EA; Zeringue A; Martin KJ
    Am J Kidney Dis; 2007 Jul; 50(1):59-68. PubMed ID: 17591525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
    Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
    Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
    BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
    Trakarnvanich T; Chalapipat O; Disthabanchong S; Kurathong S; Praditpornsilpa K; Stitchantrakul W; Chailurkit LO
    J Med Assoc Thai; 2010 Aug; 93(8):885-91. PubMed ID: 20718162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
    Blair D; Byham-Gray L; Lewis E; McCaffrey S
    J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
    Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
    Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
    Sprague SM; Silva AL; Al-Saghir F; Damle R; Tabash SP; Petkovich M; Messner EJ; White JA; Melnick JZ; Bishop CW
    Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity in serum 25-hydroxy-vitamin D response to cholecalciferol in elderly women with secondary hyperparathyroidism and vitamin D deficiency.
    Giusti A; Barone A; Pioli G; Girasole G; Razzano M; Pizzonia M; Pedrazzoni M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2010 Aug; 58(8):1489-95. PubMed ID: 20646099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial.
    Shroff R; Wan M; Gullett A; Ledermann S; Shute R; Knott C; Wells D; Aitkenhead H; Manickavasagar B; van't Hoff W; Rees L
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):216-23. PubMed ID: 22266572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5.
    Gravesen E; Hofman-Bang J; Lewin E; Olgaard K
    Scand J Clin Lab Invest; 2013 Mar; 73(2):107-16. PubMed ID: 23281842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease.
    DeVille J; Thorp ML; Tobin L; Gray E; Johnson ES; Smith DH
    Nephrology (Carlton); 2006 Dec; 11(6):555-9. PubMed ID: 17199797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
    Moe SM; Saifullah A; LaClair RE; Usman SA; Yu Z
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):299-306. PubMed ID: 20056760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly.
    Romagnoli E; Mascia ML; Cipriani C; Fassino V; Mazzei F; D'Erasmo E; Carnevale V; Scillitani A; Minisola S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3015-20. PubMed ID: 18492750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response effect of ergocalciferol therapy on serum 25-hydroxyvitamin D concentration during critical illness.
    Dickerson RN; Berry SC; Ziebarth JD; Swanson JM; Maish GO; Minard G; Brown RO
    Nutrition; 2015 Oct; 31(10):1219-23. PubMed ID: 26213135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL; Worcester EM; Coe FL; Sprague SM
    J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutritional vitamin D supplementation in dialysis: a randomized trial.
    Bhan I; Dobens D; Tamez H; Deferio JJ; Li YC; Warren HS; Ankers E; Wenger J; Tucker JK; Trottier C; Pathan F; Kalim S; Nigwekar SU; Thadhani R
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):611-9. PubMed ID: 25770176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.